Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Codexis, the most common co-covered peer. Enovis appears in 1 tracked Biotech story from March 16, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Codexis, the most common co-covered peer. Enovis appears in 1 tracked Biotech story from March 16, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Enovis. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Source: dailypolitical.com · themarketsdaily.com
Enovis is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
